Dana-Farber Research News 10.01.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from September 1 - 15.

By
October 1, 2026
32 min

Dana-Farber

Objective:

To highlight recently published research by Dana-Farber faculty.

Approach:

Research Overview: This newsletter summarizes research published from September 1 - 15, 2026, with a focus on studies where Dana-Farber faculty are first or senior authors.

Key Findings:

The CheckMate-274 trial shows nearly doubled median disease-free survival in high-risk urothelial carcinoma patients treated with adjuvant nivolumab compared to placebo.
Lorlatinib demonstrates unprecedented long-term progression-free survival in advanced ALK-positive non-small-cell lung cancer after 7 years, with a 55% 7-year PFS rate.
Temporary interruption of adjuvant endocrine therapy for pregnancy in HR-positive early breast cancer is feasible and safe, with comparable 5-year breast cancer-free interval to external controls.

Interpretation:

The findings prompt a reassessment of toxicity reporting methodologies in trials using immune checkpoint inhibitors and highlight the long-term benefits of lorlatinib and the safety of temporary therapy interruption for pregnancy.

Limitations:

Limited reporting of long-term adverse events in the CheckMate-274 trial.
Ongoing overall survival follow-up in the lorlatinib study has not yet met the number of events for analysis.

Conclusion:

The research highlights significant advancements in cancer treatment and the importance of considering long-term outcomes and patient quality of life.